Group 1 - Several new stocks have recently been listed on the Hong Kong stock market, including Jiaxin International Resources, Shuangdeng Co., Yinnuo Pharmaceutical-B, and Zhonghui Biotechnology-B, which performed well on their debut [2] - On September 17, a new stock named Health 160 was listed, opening over 150% higher and reaching a peak increase of 174%, before settling at a gain of 146.43% at the time of reporting [3] - Health 160's public offering was highly subscribed, with a subscription rate of 751.77 times, resulting in 3.36475 million shares being allocated for public sale, which is about 10% of the total shares offered [4][5] Group 2 - Health 160 is a leading wholesaler of medical health products and a digital healthcare service provider, offering a range of medical health products and comprehensive digital healthcare solutions [4] - As of March 31, 2025, Health 160 has connected over 44,600 healthcare institutions, including more than 14,400 hospitals, and has registered 55.2 million personal users on its platform [6] - The company's revenue for the years 2022 to 2024 was 526 million, 629 million, and 621 million RMB respectively, with losses of 120 million, 106 million, and 108 million RMB during the same periods [6]

Core Viewpoint - Health 160 (02656) was listed on the Hong Kong Stock Exchange on September 17, 2023, opening with a significant increase of 150.97%, resulting in a total market capitalization of HK$100.4 billion [1]. Company Overview - Health 160 is a Chinese wholesale distributor of medical health products and a provider of comprehensive digital healthcare solutions, offering a variety of medical health products and digital healthcare services to clients [2]. - As of March 31, 2025, Health 160 has connected over 44,600 healthcare institutions, including more than 14,400 hospitals and over 30,200 grassroots healthcare institutions [3]. - The company has established partnerships with over 902,300 healthcare professionals, including approximately 46,200 registered doctors, and has a registered user base of 55.2 million individuals [3]. Financial Performance - Health 160's revenue for the years 2022, 2023, and 2024 was RMB 525.646 million, RMB 628.606 million, and RMB 620.682 million, respectively, with corresponding losses of RMB 120.065 million, RMB 106.199 million, and RMB 108.246 million [4]. - In the first quarter of 2025, the company reported revenue of RMB 100.475 million, a year-on-year increase of 6.7%, with a loss of RMB 17.128 million compared to a loss of RMB 40.246 million in the same period the previous year [4][3]. Shareholding Structure - Prior to the IPO, Roning Zheng controlled approximately 33.99% of the voting rights through his wholly-owned companies, LNZ Management Limited and Luo Holdings Limited [5]. - Following the share split and global offering, Roning Zheng is expected to control about 34.08% of the company's issued share capital [5][6]. Leadership - Roning Zheng, the founder, executive director, chairman, and CEO of the group, has over 25 years of industry experience and is responsible for the overall strategy and management of the company [7].

Major Events - Health 160 (02656) received a subscription rate of 751.77 times for its public offering in Hong Kong, with listing scheduled for September 17 [1] - Huajian Medical (01931) and Renhe International have reached a significant strategic cooperation to establish the world's first vertical RWA exchange focused on the OTC sector [1] - Giant Legend (06683) strategically invested in the operation company of the Bird's Nest to enhance IP and landmark synergy [1] - Yuexiu Property (00123) successfully acquired the Kangqiao land in Hangzhou's Gongshu District for 1.33 billion [1] - China Jinmao (00817) plans to increase capital by 350 million to Beijing Chaoyang and 2.15 billion to Beijing Manmao [1] - Sichuan Energy Investment Development (01713) signed a construction contract with Degge Gesaer Power for development [1] - Qianxun Technology (01640) signed a memorandum of understanding for the proposed acquisition of 100% equity in Punk Code Technology [1] - GCL-Poly Energy (03800) clarified that the profit statement for August-September is not an annual forecast, but based on the trend of polysilicon prices and disclosed data [1] Operating Performance - China Shenhua (01088) reported a coal production of 28.6 million tons in August, a year-on-year decrease of 0.3% [1] - Nanshun (Hong Kong) (00411) announced annual results with a net profit of 303 million HKD, representing a year-on-year increase of 51% [1]

其中，香港公开发售获751.77倍认购，国际发售获1.92倍认购。 健康160(02656)公布配发结果，公司全球发售3364.55万股股份，香港公开发售占10%，国际发售占 90%。最终发售价为每股11.89港元，全球发售净筹约3.16亿港元。每手250股，预期股份将于2025年9月 17日(星期三)上午九时正开始在联交所买卖。 ...

格隆汇9月16日丨健康160(02656.HK)公告，公司全球发售33,645,500股股份，每股股份11.89港元，所得 款项净额3.16亿港元。香港公开发售股份数目占全球发售股份数目10.00%，获认购751.77倍；国际发售 股份数目占全球发售股份90.00%，获认购1.92倍。假设全球发售于2025年9月17日(星期三)上午八时正 (香港时间)或前成为无条件，预期股份将于2025年9月17日(星期三)上午九时正开始在联交所买卖。股份 将以每手250股股份进行买卖，股份的股份代号为2656。 ...

智通财经APP讯，健康160(02656)公布配发结果，公司全球发售3364.55万股股份，香港公开发售占 10%，国际发售占90%。最终发售价为每股11.89港元，全球发售净筹约3.16亿港元。每手250股，预期 股份将于2025年9月17日(星期三)上午九时正开始在联交所买卖。 其中，香港公开发售获751.77倍认购，国际发售获1.92倍认购。 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）和香港中央結 算有限公司（「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 本公告不得直接或間接於或向美國（包括其領土及屬地、美國任何州及哥倫比亞 特區）發佈、刊發或派發。本公告並不亦無意構成或組成在美國或任何其他司法 管轄區購買或認購證券的任何要約或招攬的一部分。發售股份並無亦不會根據 1933年美國證券法（經不時修訂）（「美國證券法」）或任何美國州或其他司法管轄區 證券法登記，且不得於美國境內提呈發售、出售、質押或以其他方式轉讓，惟獲 豁免遵守或毋須遵守美國證券法登記規定及任何適用的州證券法的交易則另作別 論。發售股份不會於美國公開發售。發售股份僅可根據美國證券法S規例及進行 有關要約及出售的各司法管轄區的適用法律在離岸交易中向美國境外的人士提呈 發售及出售。 本公告僅供參考，並不構成收購、購買或認購證券的邀請或要約。本公告並非招 股章程。有意投資者於決定是否投資所提呈發售的股份前，應細閱健康160国际 有限公司（「本公 ...

健康160(02656)将于9月17日(周三)在香港挂牌。截至收盘，利弗莫尔证券暗盘交易显示报价29港元，较招股价11.89港元上涨143.9%，每手250股，不计手续 费，每手赚4277.5港元。 分时量 量:0 10.88万 29.000 725( 28.980 28.960 28.940 MACD MACD(12,26,9):0.144 DIF:0.224 DEA:0.152 28.920 28.900 28.880 28.860 16:15 18:30 分时 日K 1分 5分 立即买入 立即卖出 • 行情来源: 利弗莫尔证券 • | 18:37 | | | | .။ ? □ | | --- | --- | --- | --- | --- | | 首页 | | | 健康160 HK 02656 暗盘 | O | | 行情 | 板块 | 评论 | 券商持仓 | 实时数 | | 29.000 | | 成交 182.84万股 最高 35.360 | | 今开 16.000 | | +143.90% +17.110 换手 0.54% | | | 最低 16.000 | 总市 97.57亿 | ...

分时量 量:0 10.88万 29.000 725( 28.980 28.960 28.940 MACD MACD(12,26,9):0.144 DIF:0.224 DEA:0.152 28.920 28.900 28.880 28.860 16:15 18:30 分时 日K 1分 5分 立即买入 立即卖出 • 行情来源: 利弗莫尔证券 • 智通财经APP获悉，健康160(02656)将于9月17日(周三)在香港挂牌。截至收盘，利弗莫尔证券暗盘交易显示报价29港元，较招股价11.89港元上涨143.9%，每 手250股，不计手续费，每手赚4277.5港元。 | 18:37 | | | | .II ? □) | | --- | --- | --- | --- | --- | | | | 健康160 | | | | 首页 | | HK 02656 暗盘 | | | | 行情 | 板块 | 评论 | 券商持仓 | 实时数 | | 29.000 | | 成交 182.84万股 最高 35.360 | | 今开 16.000 | | +143.90% +17.110 换手 0.54% | | | 最低 16.000 | ...

| 16:16 | | | .။ ? 또 | | --- | --- | --- | --- | | | 健康160 | | | | 首页 | HK 02656 暗盘 | | | | 行情 板块 | 评论 券商持仓 | | 实时数: | | 23.500 | 最高 25.000 成交 14.12万股 | | 今开 16.000 | | +97.65% +11.610 | 换手 0.04% 最低 16.000 | | 总市 79.07亿 | | 16:16 价 23.500 +97.65% 均 21.612 分时量 37250股 | | | | | 23.500 | 97.65% | | 十档 成交 | | | | 23.960 | | | | | | 23.940 | | | | | 23.920 | | | | | 23.900 | | | | | 23.880 | | 11.890 | | | 23.860 | | | | | 23.840 | | | | | 23.820 | | | | | 23.800 250 | | | | | 23.780 250 | | | | | 23.500 5500 | ...